A Multicenter Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of GR1802 Injection in Combination With Background Therapy in Patients With Seasonal Allergic Rhinitis.
Latest Information Update: 07 Oct 2025
At a glance
- Drugs Telikibart (Primary)
- Indications Seasonal allergic rhinitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Genrix (Shanghai) Biopharmaceuticals
Most Recent Events
- 07 Oct 2025 New trial record